Anosmia (Loss of Smell)

Table of Contents

1. Overview
2. Epidemiology
3. Olfactory Anatomy and Physiology
4. Post-Viral Anosmia (COVID-19 and Other Viruses)
5. Other Causes
6. Congenital Anosmia: Kallmann Syndrome
7. Diagnosis
8. Treatment
9. Parosmia and Phantosmia
10. Impact on Quality of Life and Taste
11. Prognosis and Recovery
12. Key Research Papers
13. Featured Videos

Overview

The sense of smell (olfaction) is mediated by specialized receptor neurons in the olfactory epithelium, a small patch of tissue high in the nasal cavity. When odor molecules reach this region and bind to olfactory receptors, electrical signals travel along the olfactory nerve (cranial nerve I) through tiny holes in the cribriform plate to the olfactory bulb in the brain, and then onward to the piriform cortex, amygdala, and hippocampus — brain regions central to emotion, memory, and autonomic regulation.

Anosmia refers to the complete absence of smell. Hyposmia is a reduced but not absent sense of smell. Both can be temporary or permanent, unilateral or bilateral, and congenital or acquired. The causes are diverse but fall into two broad categories: conductive (a physical barrier preventing odorant molecules from reaching the olfactory epithelium) and sensorineural (damage to the olfactory epithelium, olfactory nerve, or central olfactory pathways).

Back to Table of Contents

Epidemiology

Olfactory dysfunction is far more common than most clinicians recognize. Before the COVID-19 pandemic, large population studies suggested that approximately 3–20% of adults had some degree of olfactory impairment, with prevalence rising steeply with age — from roughly 5% in adults under 50 to over 25% in adults over 65. The US National Health and Nutrition Examination Survey (NHANES) estimated that approximately 12.4% of US adults aged 40 and older had olfactory dysfunction. That figure comes from the survey's first measured smell test (first-year results, 2012): of 1,281 adults aged 40 and older who took an 8-item smell identification test, 12.4% had smell loss (about 13.3 million adults), including 3.2% with anosmia or severe hyposmia (about 3.4 million). The rate rose from 4.2% at ages 40–49 to 12.7% at 60–69 and 39.4% at 80 and older. Among adults aged 70 and older, 20.3% could not identify the smell of smoke and 31.3% could not identify natural gas.

COVID-19 dramatically changed the epidemiological landscape. Self-reported anosmia occurred in 40–80% of patients during acute infection. An estimated 700,000 to 1.6 million Americans developed persistent anosmia lasting more than six months after COVID-19 infection, making it the most common single infectious cause of chronic olfactory loss in recorded history.

Pre-pandemic, the leading causes of acquired anosmia were:

• Post-viral anosmia: ~40% of acquired cases (primarily upper respiratory infections)
• Sinonasal disease (nasal polyps, chronic rhinosinusitis): ~20–30%
• Head trauma: ~10–15%
• Idiopathic: ~20% (no identifiable cause)
• Neurodegenerative and other causes: remaining ~10%

Anosmia is more common in men than women and increases substantially with age. It is also associated with smoking, occupational chemical exposure, and poor general health.

Back to Table of Contents

Olfactory Anatomy and Physiology

Understanding how smell works is essential to understanding why it fails. The olfactory system is anatomically unusual: it is the only cranial nerve system that projects directly to the cortex without a thalamic relay, and the olfactory epithelium is one of the only parts of the adult central nervous system capable of meaningful neuronal regeneration.

The Olfactory Epithelium

The olfactory epithelium lines a roughly 5 cm² patch on the superior nasal septum and superior turbinate. It contains three major cell types:

• Olfactory sensory neurons (OSNs): Bipolar neurons with cilia extending into the nasal mucus that express odorant receptor proteins. Humans have roughly 350 functional odorant receptor genes. OSNs have a lifespan of 30–90 days and are continuously regenerated from basal stem cells.
• Sustentacular (support) cells: Non-neuronal supporting cells that surround the OSNs, provide structural and metabolic support to them, and regulate ion balance in the mucus layer. These cells express high levels of the ACE2 receptor — the entry point for SARS-CoV-2.
• Basal stem cells: The regenerative reservoir of the olfactory epithelium. Both horizontal and globose basal cells can replenish OSNs after injury, giving the olfactory epithelium its unique regenerative capacity.

The Olfactory Pathway

Once an odorant binds to an OSN receptor, a G-protein cascade opens cyclic nucleotide-gated ion channels, depolarizing the neuron. The signal travels along unmyelinated axonal fila through approximately 20 tiny foramina in the cribriform plate of the ethmoid bone to synapse in the olfactory bulb (glomeruli). From there, projection neurons carry signals to the primary olfactory cortex (piriform cortex), the amygdala (emotional significance), the hippocampus (odor-memory association), and the entorhinal cortex (episodic memory).

The olfactory bulb itself is plastic and can undergo volume changes with use or disuse. Olfactory bulb volume measured by magnetic resonance imaging (MRI) correlates significantly with olfactory function and is reduced in anosmia. Recovery of olfactory bulb volume correlates with recovery of smell.

Back to Table of Contents

Post-Viral Anosmia (COVID-19 and Other Viruses)

COVID-19 and SARS-CoV-2 Mechanism

SARS-CoV-2 produces anosmia through a mechanism distinct from most prior respiratory viruses. The key finding — established by multiple autopsy and biopsy studies — is that the virus primarily infects sustentacular (support) cells in the olfactory epithelium, not olfactory sensory neurons themselves.

Here is the step-by-step mechanism:

1. SARS-CoV-2 spike protein binds ACE2 receptors, which are highly expressed on sustentacular cells but present at low levels on olfactory sensory neurons.
2. Sustentacular cells die or become dysfunctional. These cells regulate the ionic environment of the olfactory mucus that is essential for odorant transduction.
3. Without sustentacular support, olfactory sensory neurons lose metabolic support, stop firing, and eventually die — even though they were not directly infected.
4. The resulting inflammation in the olfactory cleft (detectable on magnetic resonance imaging as edema and mucosal thickening) further blocks odorant access.
5. Magnetic resonance imaging studies show reduced olfactory bulb volume in persistent post-COVID anosmia, suggesting secondary trans-synaptic degeneration or disuse atrophy.

A 2020 study in golden Syrian hamsters showed the sequence in plain terms. Within 2 days of the virus being dropped into the nose, the smell lining was massively damaged and had lost most of its cilia, the tiny hairs that catch odour molecules. The virus had infected a large share of the support (sustentacular) cells but not the smell neurons themselves, and no virus was found in the olfactory bulbs of the brain. Immune cells flooded the lining, which may have helped it shed, and by day 14 the lining was partly restored. The authors concluded that COVID-19 smell loss is likely linked to this fast shedding of the smell lining after the support cells are infected. These are animal results.

This mechanism explains why COVID-19 anosmia is often sudden in onset (sustentacular cell death is rapid), frequently occurs without nasal congestion (the blockage is cellular, not mucosal), and can be prolonged: olfactory sensory neuron regeneration requires a functional sustentacular scaffold that may itself need weeks to recover.

Incidence and Duration

During the original Wuhan strain and Alpha variant waves, 40–80% of symptomatic COVID-19 patients reported anosmia or hyposmia. This rate fell with Omicron variants to roughly 10–20%, possibly due to Omicron's preference for upper airway cells over olfactory epithelium, or to prior immunity. Of those affected:

• A 2022 meta-analysis in the BMJ of 18 studies (3,699 patients) found that 74.1% had recovered their sense of smell by their own report at 30 days, 85.8% at 60 days, 90.0% at 90 days and 95.7% at 180 days.
• The same analysis estimated that persistent smell loss could develop in about 5.6% of patients (95% confidence interval 2.7% to 11.0%), and the authors noted this could be an underestimate. Women, people with more severe loss at the start, and people with nasal congestion were less likely to recover.
• In a Danish study that followed people with smell loss during the COVID-19 era for a year, 42.0% reported lasting complete recovery, 41.7% partial recovery and 2.4% no improvement (follow-up was missing for 13.9%); 24.5% had smell loss come back after an initial complete recovery.

Other Post-Viral Causes

Before COVID-19, post-viral anosmia was most commonly caused by:

• Influenza A and B: Direct cytopathic effects on olfactory epithelium; accounts for a substantial fraction of pre-COVID post-viral anosmia cases.
• Parainfluenza virus: Strong association with olfactory loss, particularly in older patients.
• Rhinovirus: The most common cold virus; usually causes temporary hyposmia from conductive blockage but can cause sensorineural loss.
• Herpes simplex virus (HSV): Can cause olfactory epithelium inflammation and rarely, encephalitis affecting the olfactory bulb or cortex; associated with specific olfactory hallucinations.
• Epstein-Barr virus (EBV): Reported in association with post-infectious olfactory loss.

The mechanism in non-COVID post-viral anosmia involves direct viral cytopathic effects on the olfactory epithelium, localized immune-mediated inflammation, and edema within the olfactory cleft that restricts odorant access.

Back to Table of Contents

Other Causes

Head Trauma

Traumatic anosmia affects an estimated 5–15% of head injury patients. The most vulnerable structure is the olfactory fila — the 20 thin unmyelinated axon bundles passing from the olfactory epithelium through the cribriform plate. Sudden acceleration-deceleration forces (most commonly from frontal impact — approximately 65% of traumatic anosmia cases) shear these delicate fila as the brain moves within the skull. The cribriform plate itself may fracture.

Prognosis is variable: roughly one-third of traumatic anosmia patients experience some recovery, usually within the first 3–12 months. After 12 months with no improvement, permanent anosmia is likely. Anosmia from occipital (rear) impacts tends to be more severe and less likely to recover, possibly because the shear forces are transmitted to the olfactory bulb and tract directly.

Nasal Polyps and Chronic Rhinosinusitis

Chronic rhinosinusitis with nasal polyps (CRSwNP) is the most common reversible cause of anosmia. Polyps are inflammatory growths in the nasal cavity and sinuses that physically obstruct airflow to the olfactory cleft, preventing odorant molecules from reaching the olfactory epithelium. The obstruction is conductive, not sensorineural, which means that reducing the polyps often restores smell.

Management options include:

• Intranasal corticosteroid sprays (fluticasone, mometasone): First-line; reduce polyp size and mucosal edema.
• Oral corticosteroid bursts: More effective for rapid reduction but not suitable for long-term use.
• Dupilumab: A monoclonal antibody targeting the IL-4 receptor alpha subunit, blocking both IL-4 and IL-13 signaling. Pivotal trials showed significant reduction in nasal polyp size and significant improvement in smell scores. In the two phase 3 trials SINUS-24 and SINUS-52 (276 and 448 adults with severe polyps), dupilumab 300 mg every 2 weeks reduced the nasal polyp score by about 2 points more than placebo at 24 weeks (−2.06 and −1.80). Dupilumab represents a major advance for type-2 inflammatory polyp disease.
• Tezepelumab: A newer monoclonal antibody tested in the 2025 WAYPOINT trial of 408 adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps, given by injection every 4 weeks for 52 weeks on top of standard care. It shrank the polyps (nasal polyp score −2.07 versus placebo), improved the loss-of-smell score (−1.00 versus placebo), and surgery for polyps was judged necessary in 0.5% of patients on tezepelumab against 22.1% on placebo.
• Functional endoscopic sinus surgery (FESS): Removes polyps and opens sinus drainage pathways; effective but recurrence is common without ongoing medical management.

Neurodegenerative Diseases

Olfactory dysfunction is a recognized early feature of several neurodegenerative conditions, sometimes predating motor or cognitive symptoms by years:

• Parkinson's disease: Hyposmia or anosmia is present in approximately 90% of patients. Alpha-synuclein pathology (Lewy bodies) appears in the olfactory bulb very early in Parkinson's disease, consistent with Braak's staging hypothesis that the disease may begin in olfactory and gut tissue before spreading centrally. Olfactory testing has been studied as a biomarker for preclinical Parkinson's disease.
• Alzheimer's disease: Smell identification deficits are among the earliest detectable sensory changes. The entorhinal cortex, which processes olfactory information, is one of the first regions to accumulate tau pathology in Alzheimer's disease.
• Lewy body dementia: Severe olfactory loss, similar to Parkinson's disease, reflecting shared alpha-synuclein pathology.

Sinonasal and Inflammatory Diseases

• Allergic rhinitis: Seasonal or perennial allergen exposure causes mucosal edema that reduces odorant access; usually associated with hyposmia rather than anosmia.
• Chronic rhinosinusitis without polyps (CRSsNP): Mucosal thickening and edema in the olfactory cleft region impair odorant delivery.
• Granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis): A systemic vasculitis that affects the upper respiratory tract, causing destructive sinonasal disease and olfactory loss.
• Sarcoidosis: Granulomatous inflammation can affect the olfactory bulb and nasal mucosa.

Medications and Toxins

A range of medications can impair olfaction through various mechanisms including direct olfactory epithelium toxicity, central effects, or metal ion dysregulation:

• Methotrexate: Antifolate agent; may disrupt olfactory epithelium turnover.
• Carbimazole and methimazole: Thyroid medications associated with taste and smell loss.
• Calcium channel blockers (nifedipine): Associated with taste and smell disturbances.
• Aminoglycoside antibiotics: Gentamicin and others have direct cytotoxic effects on olfactory epithelium at high intranasal concentrations.
• Intranasal zinc sulfate (ZnSO4): Historically studied as a polio prophylactic in the 1930s–1940s and as a rhinovirus treatment in the 1990s. High-concentration intranasal zinc sulfate caused permanent anosmia — now a cautionary example of iatrogenic olfactory loss.
• Intranasal zinc: A 2006 case series described 17 people who lost their sense of smell after using intranasal zinc gluconate cold gels. All reported sniffing deeply when applying the gel, followed at once by a burning feeling lasting minutes to hours, with smell loss noticed within 48 hours; 7 of the 17 never developed cold symptoms. The authors called it the zinc-induced anosmia syndrome — "squirt, sniff, burn, and anosmia" — caused by exposure of the smell lining to the zinc ion.

Zinc Deficiency

Zinc is critical for the function of the olfactory epithelium. The olfactory mucus contains zinc-binding proteins. Zinc deficiency — common in older adults, alcoholism, and malabsorption syndromes — is associated with hyposmia. Oral zinc supplementation has shown benefit in some studies of zinc-deficient anosmia patients, though evidence is modest and zinc excess is also harmful.

Back to Table of Contents

Congenital Anosmia: Kallmann Syndrome

Kallmann syndrome is a rare congenital disorder characterized by the combination of anosmia (or severe hyposmia) and hypogonadotropic hypogonadism — the failure of gonadotropin-releasing hormone (GnRH) neurons to properly migrate from the olfactory placode to the hypothalamus during fetal development. Because GnRH neurons migrate along olfactory axon pathways, defects in olfactory nerve development impair both smell and reproductive axis development simultaneously.

Genetics

Kallmann syndrome is genetically heterogeneous:

• KAL1 / ANOS1 gene (X-linked): The most common X-linked form. Encodes anosmin-1, an extracellular matrix protein required for olfactory axon guidance and GnRH neuron migration. Affects primarily males.
• FGFR1 (KAL2): Autosomal dominant; fibroblast growth factor receptor 1 mutations disrupt olfactory axon and GnRH neuron development.
• PROKR2 and PROK2: Prokineticin receptor 2 and prokineticin 2 mutations; autosomal recessive or dominant; involved in olfactory bulb morphogenesis.
• CHD7, FGF8, GNRHR, KISS1R, and others: Additional genes account for further cases, reflecting the complexity of olfactory and GnRH developmental pathways.

Clinical Presentation

Kallmann syndrome affects males more severely and more frequently than females (approximately 4:1 ratio). Key features include:

• Absent or severely reduced sense of smell (often lifelong; the patient may not realize they lack smell until specifically tested)
• Absent or severely delayed puberty in males: no testicular growth, no voice deepening, no facial hair
• Micropenis and undescended testes (cryptorchidism) in some males
• Absent or very low luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone on laboratory testing
• Magnetic resonance imaging: absent or hypoplastic olfactory bulbs — a key diagnostic finding

Associated features include mirror movements (synkinesis) in ANOS1 mutations, unilateral renal agenesis, cleft palate, and hearing loss depending on the genetic subtype.

Treatment

Anosmia in Kallmann syndrome is generally permanent — the olfactory bulbs are absent or severely hypoplastic and do not develop postnatally. Management focuses on the hormonal deficiency:

• Pulsatile GnRH pump therapy: Most physiologic; mimics hypothalamic GnRH secretion; can restore fertility in both males and females.
• Gonadotropin therapy (follicle-stimulating hormone + hCG injections): Stimulates testicular/ovarian function; used for fertility induction.
• Testosterone replacement (males): For masculinization (muscle mass, sexual function, bone density) in men not seeking fertility.
• Estrogen-progesterone therapy (females): For feminization and bone protection.

Back to Table of Contents

Diagnosis

Clinical History

A thorough history establishes the time course (sudden vs. gradual), unilateral vs. bilateral, presence of associated symptoms (nasal congestion, rhinorrhea, facial pain, neurological symptoms), recent viral illness, head trauma, medication changes, and family history. The onset timing often points to the cause: sudden onset after a respiratory infection suggests post-viral; gradual onset with congestion and facial pressure suggests sinonasal disease; gradual onset with tremor or memory concerns suggests neurodegenerative disease.

Psychophysical Smell Testing

Objective smell testing is essential — self-reported olfactory ability correlates poorly with measured function. Validated tools include:

• University of Pennsylvania Smell Identification Test (UPSIT): 40-item scratch-and-sniff forced-choice test; widely used in the United States; takes approximately 15 minutes; scores range from 0 (total anosmia) to 40 (normal). Validated age- and sex-normed scores available.
• Sniffin' Sticks (Extended Test): European standard; 16-item identification test plus optional threshold and discrimination components; yields a composite "TDI score" (threshold, discrimination, identification).
• Connecticut Chemosensory Clinical Research Center (CCCRC) Test: Combines n-butanol threshold testing with identification of 8 common household odorants.

Nasal Endoscopy

Flexible or rigid nasal endoscopy is performed to assess the nasal cavity for polyps, mucosal edema, septal deviation, masses, or crusting. It visualizes the olfactory cleft region directly — edema or secretions in the olfactory cleft indicate a conductive or inflammatory component.

Imaging

• Magnetic resonance imaging with dedicated coronal olfactory bulb sequences: Evaluates olfactory bulb size and morphology (absent in Kallmann syndrome; reduced in post-viral and post-traumatic anosmia), olfactory cleft edema (post-COVID, post-viral), skull base anatomy, and any central causes (olfactory groove meningioma, frontal lobe pathology).
• Computed tomography (CT) of paranasal sinuses: Best for assessing sinonasal anatomy, polyp burden, cribriform plate integrity (in trauma), and sinus opacification. Often the first-line imaging for suspected sinonasal disease.

Laboratory Tests

Depending on clinical context: serum zinc level (zinc deficiency-associated hyposmia), luteinizing hormone/follicle-stimulating hormone/testosterone (Kallmann syndrome workup), antineutrophil cytoplasmic antibody (ANCA) panel (granulomatosis with polyangiitis), immunoglobulin E (IgE) and allergen-specific testing (allergic rhinitis).

Back to Table of Contents

Treatment

Olfactory Training (Hummel Protocol)

Olfactory training is the best-evidenced intervention for post-viral and post-traumatic anosmia. The protocol was developed by Dr. Thomas Hummel at the University of Dresden and first described in a 2009 prospective study that was not randomized: 40 patients trained for 12 weeks, sniffing four intense odours twice a day, while 16 patients did not train. Smell scores rose in the patients who trained and were unchanged in those who did not.

Standard Hummel Protocol:

• Four scent categories: rose (floral), lemon (fruity), cloves (aromatic/spicy), and eucalyptus (resinous). These represent the four principal odor categories in the Henning odor prism classification.
• Each scent is sniffed actively and consciously for 20 seconds, twice daily (morning and evening).
• Minimum duration: 12–16 weeks. Evidence suggests 32–56 weeks of training may produce better outcomes.
• The protocol uses high-concentration essential oils or ready-made training kits so that the odour stimulus is strong enough.

Modified protocols with higher-concentration odorants, longer training durations (up to 56 weeks), and odorant switching (changing the four scents mid-course to expose the olfactory system to new stimuli) have shown additional benefit in some studies. The rationale is neuroplasticity: active sniffing stimulates olfactory sensory neuron axon regrowth, olfactory epithelium regeneration, and central olfactory processing adaptation.

Evidence: A 2017 meta-analysis of 13 studies found a significant benefit of olfactory training for every smell ability tested, with large effects on smell identification, smell discrimination and the combined TDI score, and a small-to-moderate effect on the threshold for detecting odours; training duration influenced the gains in identification. Evidence for COVID-19 smell loss specifically is thinner: the 2022 Cochrane living review of treatments for persistent smell loss after COVID-19 included only two small trials (30 people), neither of them a training trial, and concluded that "there is very limited evidence available on the efficacy and harms of treatments." The original Hummel 2009 study: PubMed PMID: 19235739.

A 2023 randomized trial in 275 adults with smell loss lasting 3 months or more after COVID-19 compared training styles: participants sniffed 4 essential oils for 15 seconds each, with 30-second rests, for 3 months, using either physician-assigned scents (rose, lemon, eucalyptus and clove) or 4 scents they chose from 24, with or without pictures of each scent. The main measure (change in UPSIT score) did not differ between the training styles. However, a clinically important UPSIT improvement was seen in 53% of the group that trained with pictures and self-chosen scents, against 24% of an untrained control group.

Corticosteroids

• Oral corticosteroids (prednisone): A short burst (1 mg/kg/day, typically 40–60 mg/day, for 5–10 days) reduces olfactory cleft edema in acute post-viral and sinonasal anosmia. Most useful in the acute phase (first 2–4 weeks after onset). Limited evidence supports their use for chronic post-viral anosmia. Side effects at short courses are generally manageable but include hyperglycemia, mood changes, and insomnia.
• Intranasal corticosteroid sprays (fluticasone, mometasone, budesonide): First-line for sinonasal-related and allergic anosmia. Applied as directed spray to the nasal cavity with the head tilted forward and downward (vertex-to-floor position) to target the olfactory cleft. Less effective for post-viral sensorineural anosmia but appropriate when mucosal inflammation is a contributing factor.

Platelet-Rich Plasma (PRP) Intranasal Injection

PRP is an emerging, experimental therapy for persistent post-viral anosmia. Autologous blood is centrifuged to concentrate platelets and growth factors (including PDGF, VEGF, TGF-beta, EGF), which are then injected into the olfactory cleft region under endoscopic guidance. The rationale is that platelet-derived growth factors promote olfactory epithelium regeneration and sustentacular cell recovery.

A 2023 randomized controlled trial tested PRP in people whose smell loss after COVID-19 had lasted 6 to 12 months. Patients received three injections of either PRP or sterile saline into the olfactory cleft; 35 were recruited and 26 completed the study. At 3 months, smell scores on the Sniffin' Sticks test improved by 3.67 points more with PRP than with saline, and 57.1% of the PRP group reached a clinically important improvement against 8.3% of the saline group. Smell discrimination improved, but smell identification, threshold and patients' own ratings of their smell did not differ from saline. No adverse effects were reported. However, PRP for anosmia is not yet standard of care and requires further validation in larger randomized trials. The procedure requires an otolaryngologist with endoscopic training.

PubMed search: PubMed: platelet rich plasma anosmia intranasal

Other Pharmacological Approaches

• Omega-3 fatty acids: Animal studies suggest omega-3 supplementation promotes olfactory epithelium regeneration and neural survival. Preliminary human data show modest benefit; ongoing randomized controlled trials (RCTs) underway for post-COVID anosmia.
• Alpha-lipoic acid: A mitochondrial antioxidant studied in post-viral olfactory loss. Results have been mixed across trials, with some showing benefit particularly in combination with olfactory training.
• Theophylline nasal drops: Off-label use, primarily in post-traumatic anosmia. Theophylline is a phosphodiesterase inhibitor; it may increase cyclic AMP in olfactory sensory neuron signaling cascades. Small studies show benefit; not widely available in this formulation in the US.
• Sodium citrate nasal rinse: Preliminary evidence for temporary improvement in olfactory sensitivity; mechanism uncertain; may interact with calcium ions in olfactory mucus.
• Dupilumab: Specifically for CRSwNP-related anosmia; dramatically effective in appropriately selected patients (type-2 inflammatory disease).

Surgical Approaches

Functional endoscopic sinus surgery (FESS) is indicated when polyp burden or chronic sinusitis does not respond adequately to medical management. Surgery opens the olfactory cleft by removing obstructing polyps and resecting the uncinate process to improve drainage. For post-traumatic anosmia with cerebrospinal fluid (CSF) leak or meningoencephalocele through a cribriform plate fracture, surgical repair is essential to prevent meningitis.

Back to Table of Contents

Parosmia and Phantosmia

Parosmia: Distorted Smell Perception

Parosmia is a qualitative distortion of smell: real odors are perceived as different — and usually unpleasant — smells. Common trigger odors include coffee, cooked meat, onions, garlic, and toothpaste, which are perceived as rotting, sulfurous, sewage-like, or chemical. Foods that were previously enjoyable become repulsive, leading to food aversion, weight loss, and significant psychological distress.

A 2024 clinic study found that parosmia was 3.5 times more likely after post-viral smell loss and was typically seen in younger women with a shorter duration of smell loss, while phantosmia was seen more in older people with longer-lasting smell loss of unknown cause. In a 2022 questionnaire study of 271 people with smell loss, 251 with parosmia and 166 with normal smell, parosmia was linked to more frequent weight loss, and both groups reported less comfort and inspiration in cooking; the researchers suggested adapting meals to include "safer food items" and integrating stimulation of the other senses as a possible way to regain enjoyment of food.

Parosmia is thought to be a sign of olfactory nerve regeneration. It is believed to occur when regenerating olfactory sensory neurons rewire incorrectly to olfactory bulb glomeruli — sending the wrong pattern signals for a given odor. In post-COVID anosmia, parosmia most commonly begins 3–6 months after the initial smell loss, as new neurons start regrowing. It usually (though not always) resolves over months to years as rewiring matures. Olfactory training may accelerate resolution.

Management is supportive: identifying trigger foods and leaving them out for a time, dietary counseling, and psychological support for the emotional impact. "Parosmia safe foods" are foods that smell neutral or pleasant to most parosmia patients — typically plain starches, dairy, and certain fruits. Online patient communities (AbScent, Fifth Sense) have compiled these lists.

Phantosmia: Olfactory Hallucinations

Phantosmia refers to perceived odors without any external odorant source — olfactory hallucinations. Common descriptions include burning, smoke, chemical, rotten, or sweet odors. Phantosmia is told apart from parosmia (present stimulus, distorted perception) through careful history-taking.

Causes of phantosmia include:

• Recovery phase from olfactory epithelium damage (spontaneous neuronal firing from regenerating neurons)
• Epilepsy (olfactory aura of temporal lobe seizures — the "uncinate fit" of Hughlings Jackson)
• Migraine aura
• Nasal or sinus pathology (local irritation causing aberrant neuronal firing)
• Psychiatric conditions (schizophrenia, severe depression)
• Rarely, olfactory groove meningioma or other central lesions

Brain imaging is used in persistent or distressing phantosmia to rule out central causes. Treatment depends on the underlying etiology; anticonvulsants, antidepressants, and — in refractory nasal-source cases — saline irrigation or even local anesthetic have been tried with variable success.

Back to Table of Contents

Impact on Quality of Life and Taste

Smell and Flavor: A Crucial Distinction

Patients with anosmia often say "I've lost my taste" — but taste (sweet, salty, sour, bitter, umami) is mediated by taste receptor cells on the tongue and is separate from olfaction. What is commonly called "flavor" is 70–90% retronasal olfaction — the movement of volatile odor molecules from food in the mouth up through the nasopharynx to the olfactory epithelium during chewing and swallowing. Anosmia destroys flavor while leaving the five basic tastes intact. Patients can still taste that food is sweet or salty but cannot identify apple from grape, coffee from tea, or beef from chicken.

This distinction is not merely semantic: it helps clinicians counsel patients accurately, and it explains why anosmia causes such dramatic changes in eating behavior despite intact basic taste function.

Practical Safety Risks

Anosmia eliminates an evolutionarily ancient warning system. Patients cannot detect:

• Natural gas and propane leaks: (Both gases are odorless naturally; utility companies add mercaptans specifically so people can smell them. Anosmia patients cannot.) This is the single largest safety risk. In the US national survey, 31.3% of adults aged 70 and older could not identify natural gas by smell. Carbon monoxide has no smell for anyone, so only a detector reveals it; for people without smell, gas detectors and smoke alarms give the warning the nose would otherwise give.
• Smoke and fire: Until visual evidence appears.
• Spoiled food: Only date labels and appearance remain as clues.
• Body odor: Difficulty monitoring personal hygiene.

Psychological and Social Impact

Studies consistently show that anosmia is associated with significantly elevated rates of depression and anxiety. Loss of smell disrupts food pleasure, social bonding (olfactory signals play underappreciated roles in partner attraction and infant-parent bonding), and emotional memory (the "Proustian memory" effect — many autobiographical memories are olfactory-triggered). Studies report that patients with chronic anosmia have quality-of-life scores comparable to patients with moderate hearing loss. Patient charities such as AbScent (UK) and Fifth Sense run peer support groups.

Back to Table of Contents

Prognosis and Recovery

Prognosis depends heavily on etiology:

• Sinonasal (conductive) anosmia: Best prognosis. Treating the underlying polyps or rhinosinusitis often restores smell, sometimes fully. Dupilumab in CRSwNP has shown dramatic smell score improvements in controlled trials.
• Post-viral (non-COVID): Approximately 30–60% recover meaningful olfactory function within 6–12 months; a subset have permanent loss.
• Post-COVID: In a 2022 meta-analysis of 18 studies, 74.1% recovered smell by their own report within 30 days and 95.7% by 180 days; persistent smell loss was estimated at about 5.6%, which the authors noted could be an underestimate. Active olfactory training during recovery is associated with better outcomes.
• Post-traumatic: Recovery less likely than post-viral; roughly one-third improve, mostly within the first 12 months. Severe cribriform plate fractures carry the poorest prognosis.
• Neurodegenerative: Progressive loss expected in parallel with underlying disease progression. No specific therapy reverses the olfactory deficit.
• Congenital (Kallmann syndrome): Permanent anosmia; no restorative treatment available.

Predictors of Recovery

Favorable prognostic factors include: younger age, shorter duration of anosmia before treatment, hyposmia rather than complete anosmia at baseline, preserved olfactory bulb volume on magnetic resonance imaging, and engagement with olfactory training. Smoking is a significant adverse prognostic factor. Parosmia during the recovery phase is thought to reflect nerve regrowth, but in a Danish one-year follow-up of smell loss during the COVID-19 era, parosmia, more severe smell loss and female sex were each linked to lower recovery rates.

Back to Table of Contents

Key Research Papers

Olfactory Training

1. Hummel T, Rissom K, Reden J, Hähner A, Weidenbecher M, Hüttenbrink KB. Effects of olfactory training in patients with olfactory loss. Laryngoscope. 2009;119(3):496-499. — PubMed PMID: 19235739
2. Sorokowska A, Drechsler E, Karwowski M, Hummel T. Effects of olfactory training: a meta-analysis. Rhinology. 2017;55(1):17-26. — PubMed PMID: 28040824
3. O'Byrne L, Webster KE, MacKeith S, et al. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2022;9(9):CD013876. — PubMed PMID: 36062970
4. Khan AM, Piccirillo J, Kallogjeri D, Piccirillo JF. Efficacy of combined visual-olfactory training with patient-preferred scents as treatment for patients with COVID-19 resultant olfactory loss: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2023;149(2):141-149. — PubMed PMID: 36580304

COVID-19 and Post-Viral Anosmia

1. Vaira LA, Deiana G, Fois AG, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases. Head Neck. 2020;42(6):1252-1258. — PubMed PMID: 32342566
2. Butowt R, Bilinska K. SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem Neurosci. 2020;11(9):1200-1203. — PubMed PMID: 32283006
3. Bryche B, St Albin A, Murri S, et al. Massive transient damage of the olfactory epithelium associated with infection of sustentacular cells by SARS-CoV-2 in golden Syrian hamsters. Brain Behav Immun. 2020;89:579-586. — PubMed PMID: 32629042
4. Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ. 2022;378:e069503. — PubMed PMID: 35896188
5. Schwab J, Fjaeldstad AW. Recovery rates and parosmia in olfactory loss during the COVID-19 era. Dan Med J. 2022;69(9):A04220271. — PubMed PMID: 36065887
6. PubMed: COVID-19 anosmia sustentacular cells mechanism
7. PubMed: COVID-19 persistent anosmia olfactory bulb MRI

Dupilumab and Tezepelumab for Nasal Polyp-Related Anosmia

1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. — PubMed PMID: 31543428
2. Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med. 2025;392(12):1178-1188. — PubMed PMID: 40106374
3. PubMed: dupilumab nasal polyp anosmia randomized trial

Platelet-Rich Plasma

1. Yan CH, Jang SS, Lin HC, et al. Use of platelet-rich plasma for COVID-19-related olfactory loss: a randomized controlled trial. Int Forum Allergy Rhinol. 2023;13(6):989-997. — PubMed PMID: 36507615
2. PubMed: PRP intranasal injection anosmia olfactory recovery

Smell Loss in the Population, Intranasal Zinc and Parosmia

1. Hoffman HJ, Rawal S, Li CM, Duffy VB. New chemosensory component in the U.S. National Health and Nutrition Examination Survey (NHANES): first-year results for measured olfactory dysfunction. Rev Endocr Metab Disord. 2016;17(2):221-240. — PubMed PMID: 27287364
2. Alexander TH, Davidson TM. Intranasal zinc and anosmia: the zinc-induced anosmia syndrome. Laryngoscope. 2006;116(2):217-220. — PubMed PMID: 16467707
3. Sekine R, Hernandez AK, Overbeck C, et al. Comparison of patient characteristics and olfactory sensitivity for trigger odorants in parosmia and phantosmia. Laryngoscope. 2024;134(7):3277-3285. — PubMed PMID: 38578016
4. Fjaeldstad AW, Smith B. The effects of olfactory loss and parosmia on food and cooking habits, sensory awareness, and quality of life—a possible avenue for regaining enjoyment of food. Foods. 2022;11(12):1686. — PubMed PMID: 35741884

Kallmann Syndrome

1. PubMed: Kallmann syndrome ANOS1 KAL1 olfactory bulb genetics

Parkinson's Disease and Olfactory Loss

1. PubMed: Parkinson's disease anosmia alpha-synuclein olfactory bulb

PubMed Topic Searches

1. PubMed: anosmia COVID-19 recovery
2. PubMed: olfactory training smell loss
3. PubMed: post-viral anosmia treatment
4. PubMed: Kallmann syndrome anosmia
5. PubMed: nasal polyp anosmia dupilumab
6. PubMed: parosmia phantosmia treatment
7. PubMed: platelet rich plasma anosmia
8. PubMed: olfactory bulb volume MRI anosmia
9. PubMed: zinc deficiency olfaction smell
10. PubMed: anosmia head trauma cribriform plate

Back to Table of Contents

Connections

• ENT
• Sinusitis
• Dysphagia
• Tonsillitis
• Vertigo & Ménière's Disease
• Epistaxis (Nosebleeds)
• Parkinson's Disease
• Alzheimer's Disease & Neurology
• Zinc
• Vitamin A
• Ginkgo Biloba

Back to Table of Contents

Featured Videos